Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamas Pharma (ADMS)

Adamas Pharma (ADMS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,056
  • Shares Outstanding, K 28,158
  • Annual Sales, $ 54,640 K
  • Annual Income, $ -105,190 K
  • 60-Month Beta 1.81
  • Price/Sales 1.39
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.60
  • Number of Estimates 6
  • High Estimate -0.52
  • Low Estimate -0.75
  • Prior Year -0.90
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.43 +8.02%
on 06/25/20
2.98 -12.00%
on 06/17/20
-0.19 (-6.91%)
since 06/12/20
3-Month
2.43 +8.02%
on 06/25/20
3.68 -28.67%
on 04/20/20
-0.65 (-19.97%)
since 04/14/20
52-Week
1.90 +38.16%
on 03/18/20
7.78 -66.26%
on 09/23/19
-3.38 (-56.25%)
since 07/12/19

Most Recent Stories

More News
Adamas Announces New Employment Inducement Grant

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company's board of directors granted three new employees the option to purchase an aggregate of 62,500...

ADMS : 2.66 (+1.14%)
Adamas Pharmaceu Set to Possibly Rebound After Yesterday's Selloff of 3.14%

Adamas Pharmaceu (NASDAQ:ADMS) traded in a range yesterday that spanned from a low of $2.63 to a high of $2.86. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $2.70...

ADMS : 2.66 (+1.14%)
Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the...

ADMS : 2.66 (+1.14%)
Mallinckrodt Closes Rolling BLA Filing for StrataGraft Tissue

Mallinckrodt (MNK) completes the rolling submission of a BLA for StrataGraft regenerative skin tissue to treat adults with deep partial-thickness thermal burns

AMPH : 19.84 (+0.46%)
ADMS : 2.66 (+1.14%)
MNK : 2.68 (+0.37%)
ASMB : 22.70 (-1.30%)
Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI(R) to include treatment for Parkinson's disease patients receiving levodopa and experiencing OFF episodes

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that...

ADMS : 2.66 (+1.14%)
Adamas to Present at Upcoming William Blair Conference

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced...

ADMS : 2.66 (+1.14%)
Nutanix (NTNX) to Post Q3 Earnings: What Lies in Store?

Nutanix's (NTNX) third-quarter fiscal 2020 results are likely to have benefited from demand for its hybrid cloud solutions.

NVDA : 396.45 (-1.40%)
PANW : 240.04 (-0.42%)
ADMS : 2.66 (+1.14%)
NTNX : 20.53 (-2.24%)
Intuit (INTU) to Report Q3 Earnings: What's in the Cards?

Intuit's (INTU) fiscal Q3 earnings are likely to have gained from buoyant demand for Quickbooks Online. However, an extension on tax filing deadline is likely to have weighed on the top line.

CSCO : 45.75 (-0.39%)
NVDA : 396.45 (-1.40%)
INTU : 288.41 (-3.10%)
ADMS : 2.66 (+1.14%)
Palo Alto (PANW) to Report Q3 Earnings: What Lies in Store?

Palo Alto's (PANW) third-quarter fiscal 2020 earnings are likely to have gained from the strong adoption of Prisma and Cortex platforms.

CSCO : 45.75 (-0.39%)
NVDA : 396.45 (-1.40%)
PANW : 240.04 (-0.42%)
ADMS : 2.66 (+1.14%)
Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson's disease - expands coverage with reduction of 'OFF' time and increased 'good ON' time

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it...

ADMS : 2.66 (+1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ADMS with:

Business Summary

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone...

See More

Key Turning Points

2nd Resistance Point 2.86
1st Resistance Point 2.74
Last Price 2.66
1st Support Level 2.57
2nd Support Level 2.52

See More

52-Week High 7.78
Fibonacci 61.8% 5.53
Fibonacci 50% 4.84
Fibonacci 38.2% 4.15
Last Price 2.66
52-Week Low 1.90

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar